Signaturefd LLC Buys 1,151 Shares of Xencor, Inc. (NASDAQ:XNCR)

Signaturefd LLC boosted its stake in Xencor, Inc. (NASDAQ:XNCR) by 367.7% in the fourth quarter, HoldingsChannel reports. The firm owned 1,464 shares of the biopharmaceutical company’s stock after acquiring an additional 1,151 shares during the period. Signaturefd LLC’s holdings in Xencor were worth $31,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Primecap Management Co. CA grew its position in Xencor by 5.6% in the 3rd quarter. Primecap Management Co. CA now owns 8,184,206 shares of the biopharmaceutical company’s stock worth $164,912,000 after purchasing an additional 433,354 shares during the period. Armistice Capital LLC grew its position in shares of Xencor by 65.7% during the 3rd quarter. Armistice Capital LLC now owns 1,478,000 shares of the biopharmaceutical company’s stock valued at $29,782,000 after acquiring an additional 586,000 shares during the period. Invesco Ltd. grew its position in shares of Xencor by 4.6% during the 3rd quarter. Invesco Ltd. now owns 555,809 shares of the biopharmaceutical company’s stock valued at $11,200,000 after acquiring an additional 24,303 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Xencor by 2.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 488,447 shares of the biopharmaceutical company’s stock worth $9,842,000 after purchasing an additional 10,346 shares during the period. Finally, Hudson Bay Capital Management LP raised its holdings in Xencor by 144.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company’s stock worth $4,685,000 after purchasing an additional 137,500 shares during the period.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 1,280 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a total transaction of $30,080.00. Following the completion of the transaction, the vice president now directly owns 186,433 shares of the company’s stock, valued at $4,381,175.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Xencor news, VP John R. Desjarlais sold 1,280 shares of Xencor stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a total value of $30,080.00. Following the completion of the transaction, the vice president now directly owns 186,433 shares of the company’s stock, valued at approximately $4,381,175.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bassil I. Dahiyat sold 12,528 shares of Xencor stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the completion of the transaction, the chief executive officer now directly owns 300,097 shares of the company’s stock, valued at $7,031,272.71. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,351 shares of company stock valued at $2,152,417. Corporate insiders own 4.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Mizuho cut their price target on Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 22nd. Royal Bank of Canada reissued an “outperform” rating and issued a $32.00 target price on shares of Xencor in a report on Wednesday, February 28th. StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research note on Saturday, March 9th. BMO Capital Markets dropped their price target on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Finally, Piper Sandler reissued a “neutral” rating and issued a $24.00 price objective (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Xencor Stock Performance

XNCR opened at $24.11 on Friday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -11.48 and a beta of 0.77. The company has a fifty day moving average of $21.88 and a 200 day moving average of $20.47. Xencor, Inc. has a fifty-two week low of $16.49 and a fifty-two week high of $28.96. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36.

Xencor (NASDAQ:XNCR) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67). The company had revenue of $44.70 million for the quarter, compared to analysts’ expectations of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The business’s revenue was up 106.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.20) earnings per share. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.